C4 Therapeutics Inc

-0.16 (-1.87%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)411.72M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$9.87 Million
Adjusted EPS-$0.74
See more estimates
10-Day MA$8.56
50-Day MA$8.80
200-Day MA$11.51
See more pivots

C4 Therapeutics Inc Stock, NASDAQ:CCCC

490 Arsenal Way, Suite 120, Watertown, Massachusetts 02472
United States of America
Phone: +1.617.231.0700
Number of Employees: 121


C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.